NCT07491211 2026-03-27
Osimertinib Combined With Intracranial SRT for EGFR-Mutant NSCLC With Symptomatic Brain Metastases
Fudan University
Active not recruiting
Clinical Trials
11 trialsNCT02971501 2026-03-17
Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT07206498 2025-11-28
WAYWIN103
Wayshine Biopharm, Inc.
Phase 1/2 Recruiting
NCT04233021 2025-02-03
ORBITAL
Intergroupe Francophone de Cancerologie Thoracique
Phase 2 Completed
NCT05948813 2024-11-21
TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases
TYK Medicines, Inc
Phase 2 Recruiting
NCT03769103 2024-10-31
Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLC
British Columbia Cancer Agency
Phase 2 Active not recruiting
NCT05120960 2024-04-17
A Phase 1a/1b Study to Determine the Recommended Phase 2 Dose, of Tepotinib in Participants With MET Alterations and Brain Tumors
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT06319950 2024-03-20
High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases
Taizhou Hospital
Phase 2 Not yet recruiting
NCT02736513 2021-09-02
Intracranial Activity of AZD9291 (TAGRISSO) in Advanced EGFRm NSCLC Patients With Asymptomatic Brain Metastases
Soroka University Medical Center
Phase 2 Unknown
NCT02228369 2021-01-05
BLOOM
AstraZeneca
Phase 1 Completed
NCT02972333 2016-11-23
Open Label, Prospective Study to Investigate Efficacy and Safety of AZD9291 in BM From NSCLC Patients With EGFR T790M
Shandong Cancer Hospital and Institute
Phase 3 Unknown